As a major advance towards training the next generation of experts that will tailor pharmacological treatment regimens to the individual genetic makeup, the ICEPHA has established a graduate program focusing on “Membrane-associated Drug Targets in Personalized Cancer Medicine”. Since the launch of the program in 2014, our young graduates work on different aspect of tumor cell biology, on risk and prognosis prediction, and the molecular mechanisms of resistance to cancer therapy. This research is designed to bridge the gap that exists between discovery and translation, allowing a rapid integration of our results into clinical practice in order to improve outcomes for people with cancer i.e. breast cancer, hepatocellular carcinoma, glioblastoma, and other tumor entities. The second call for the ICEPHA Graduate Program was opened in May, 2018. Launching of follow-up projects is planned for November 2018.